News

Three U.S. Patents Awarded for Mirari's MASC™ Microwave Technology

The United States Patent and Trademark Office recently awarded three patents to Mirari Biosciences, Inc. The patents comprehensively cover Mirari's proprietary Microwave-Accelerated Surface Chemistry (MASC™) technology.

Rockville, MD – January 26, 2011 Mirari Biosciences recently strengthened its position as a leader in innovative biomedical technology by being awarded three U.S. Patents. The patents, numbers US 7,348,182, US 7,351,590, and US 7,718,445 broadly protect its innovative Microwave-Accelerated Surface Chemistry (MASC™) technology. The patents further certify the creativity of Mirari's research and development. MASC™ technology has promise to become extremely valuable in accelerating critical biomedical testing in many areas.

"We are happy that the U.S. Patent Office awarded these important pathbreaking patents. The patents give us even more confidence of the prospects of our many pending patents in the United States and around the world," said Mark Martin, CEO, Mirari Biosciences.

Mirari seeks to market products based on MASC™ technology alone and with corporate partners. MASC™ can enhance many applications where biomolecules are analyzed, including; pharmaceutical discovery and development, medical diagnostics, veterinary diagnostics, food testing (such as routine testing of meat, poultry, and vegetables), water testing, agricultural testing (such as for contaminant genetically modified plants on farms), and bio/chemical warfare agent testing.

About Mirari Biosciences, Inc.

Founded in 2000, Mirari is a developing platform biotechnology dedicated to streamlining Life Sciences R&D, Clinical Diagnostics, and other areas through the invention of valuable new molecular detection technologies. Mirari's MASC™, Microwave Fluidics, and Peplica™ technologies embody this mission.

Media Contact:
Mark T. Martin, Ph.D.
240-447-6456
www.miraribiosciences.com